Investment Logic - The company is leveraging its expertise in cardiovascular devices to enter the medical aesthetics market, with a product lineup that includes facial rejuvenation injections, water light injections, PDRN, and Thermage, aiming for rapid profit growth [1] - The company employs a "rural encircling urban" strategy for channel distribution, achieving over 80% coverage in large chain medical aesthetic institutions, with plans to further penetrate second and third-tier cities [1] Product Development and Market Strategy - The facial rejuvenation injection uses materials sourced from heart stents and has quickly gained market traction, generating a tax-inclusive revenue of 100 million yuan from early August to the end of October, with expectations to rank among the top three brands in the industry [2] - PDRN is anticipated to receive domestic approval by Q1 2026, positioning the company to be the first to market with a compliant PDRN injection product in a currently underserved market [2] Financial Performance and Projections - The company's traditional business is stabilizing, while the medical aesthetics, neurostimulation, and innovative pharmaceuticals are forming new growth drivers. Revenue projections for 2025, 2026, and 2027 are 6.457 billion, 7.792 billion, and 9.243 billion yuan, respectively, with year-on-year growth rates of +5.79%, +20.68%, and +18.62% [3] - The net profit attributable to shareholders is forecasted to reach 1.048 billion, 1.285 billion, and 1.531 billion yuan for the same years, reflecting significant growth of +324.34%, +22.64%, and +19.13% [3] - The company is assigned a target price of 21 yuan based on a 30x valuation for 2026, with an initial "buy" rating [3]

Core Insights - The brain-computer interface (BCI) industry is in its early commercialization stage, with a focus on thematic investment opportunities and the progress of invasive clinical trials [1] - The Chinese BCI market is projected to reach approximately 1.73 billion yuan in 2023, accounting for 12.5% of the global market [2] Group 1: Industry Trends - BCI technology is experiencing a period of accelerated transformation, with various technical paths available, including invasive, semi-invasive, and non-invasive methods, each having distinct advantages in signal quality, safety, and operational difficulty [1] - The development trend in BCI is towards multimodal applications, with existing paradigms categorized into interactive control and state detection types [1] Group 2: Policy Support - The Chinese government has outlined clear support for the BCI industry through planning, payment, and standardization, with a strategic goal set for 2027 and 2030 to foster industry clusters and leading enterprises [2] - In March 2025, the National Healthcare Security Administration established an independent billing item for BCI, providing institutional support for clinical applications [2] - Standards for BCI terminology and data formats have been introduced, reducing costs and risks in technical development and clinical applications [2] Group 3: Technological Advancements and Applications - Core technological barriers in the BCI industry are concentrated in the upstream segment, including hardware (electrodes, chips), surgical procedures, and EEG signal processing [3] - The primary functions of BCI technology encompass monitoring, replacement, recovery enhancement, and supplementation, with a wide range of applications, particularly in the medical field [3] - In 2023, medical applications accounted for 56% of the BCI market in China, focusing on diagnosing consciousness and cognitive disorders, mental illnesses, motor disabilities, and sensory deficits [3]